...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Virchows Archiv >One-step nucleic acid amplification (OSNA) for intraoperative evaluation of sentinel lymph node status in breast cancer: a comparative study between CK19 protein expression and CK19 mRNA level in primary tumors and lymph node metastasis
【24h】

One-step nucleic acid amplification (OSNA) for intraoperative evaluation of sentinel lymph node status in breast cancer: a comparative study between CK19 protein expression and CK19 mRNA level in primary tumors and lymph node metastasis

机译：一步法核酸扩增（OSNA）术中评估乳腺癌前哨淋巴结状况：CK19蛋白表达和CK19 mRNA在原发性肿瘤和淋巴结转移中的比较研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The one-step nucleic acid amplification (OSNA) method is an increasingly used procedure for intraoperative analysis of sentinel lymph node (SLN) status in breast cancer patients. It measures cytokeratin19 (CK19) mRNA copy numbers in homogenized samples of SLN; CK19 has been chosen for identifying node metastasis because most breast cancers express this molecule. However, to avoid false-negative OSNA results, testing the preoperative needle core biopsy (NCB) of breast carcinomas for CK19 by immunohistochemistry (IHC) has been recommended. This procedure relies on the assumption that protein expression is strictly related to mRNA expression. We developed this study to evaluate if IHC gives similar result to the molecular assay. In a series of breast cancer patients with axillary metastasis, corresponding surgically resected tumor and metastatic lymph node specimens have been tested for CK19 protein by IHC and for CK19 mRNA by real-time PCR; furthermore, CK19 immunostaining has been performed in NCBs when available. Statistical analysis revealed that (1) the immunohistochemical evaluation of CK19 in NCB is a reliable test, reflecting protein expression in the whole tumor and in the metastatic lymph node; (2) there is no correlation between CK19 protein expression and CK19 RNA level neither within the primary breast cancer nor within the metastatic node; moreover, no correlation as well has been found between protein expression in NCB and mRNA level in metastatic lymph nodes. Thus, our results suggest that there is no evidence-based reason to stain every NCB for CK19 before performing OSNA in patients with breast cancer.
机译：一步核酸扩增（OSNA）方法是用于乳腺癌患者术中前哨淋巴结（SLN）状况的术中分析的越来越多的程序。它测量均质SLN样品中的细胞角蛋白19（CK19）mRNA拷贝数；已选择CK19来识别淋巴结转移，因为大多数乳腺癌都表达该分子。但是，为避免OSNA假阴性，建议通过免疫组织化学（IHC）测试乳腺癌的术前CK19针头活检（NCB）。此过程基于蛋白质表达与mRNA表达严格相关的假设。我们开展了这项研究，以评估IHC是否能提供与分子分析相似的结果。在一系列患有腋窝转移的乳腺癌患者中，已通过IHC检测了相应的手术切除的肿瘤和转移性淋巴结标本的CK19蛋白，并通过实时PCR检测了CK19 mRNA。此外，在可获得的情况下，已经在NCB中进行了CK19免疫染色。统计分析表明：（1）NCB CK19的免疫组织化学评估是可靠的测试，反映了整个肿瘤和转移性淋巴结中的蛋白表达； （2）CK19蛋白表达与CK19 RNA水平在原发性乳腺癌和转移性结节之间均无相关性；此外，在NCB中的蛋白表达与转移性淋巴结中的mRNA水平之间也没有发现相关性。因此，我们的结果表明，在乳腺癌患者中进行OSNA之前，没有基于证据的理由对每个NCB的CK19进行染色。

著录项

  • 来源
    《Virchows Archiv》 |2013年第1期|7-15|共9页
  • 作者

    Enrico Pegolo; Cinzia Puppin; Anna Gerometta; Giuseppe Damante; Fabio Puglisi; Carla Di Loreto;

  • 作者单位

    Department of Medical and Biological Sciences Institution of Anatomic Pathology Azienda Ospedaliero Universitaria S. Maria della Misericordia">(1);

    Department of Medical and Biological Sciences Institution of Genetics University of Udine">(2);

    Department of Medical and Biological Sciences Institution of Genetics University of Udine">(2);

    Department of Medical and Biological Sciences Institution of Genetics University of Udine">(2);

    Department of Medical and Biological Sciences Department of Oncology University Hospital of Udine University of Udine">(3);

    Department of Medical and Biological Sciences Institution of Anatomic Pathology Azienda Ospedaliero Universitaria S. Maria della Misericordia">(1);

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Breast cancer; Sentinel lymph node; Cytokeratin19; OSNA;

    机译：乳腺癌;前哨淋巴结;细胞角蛋白19;OSNA;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号